1,2,4,6-Tetra-O-acetyl-3-deoxy-D-glucopyranose - CAS 5040-09-5
Category:
Carbohydrates
Product Name:
1,2,4,6-Tetra-O-acetyl-3-deoxy-D-glucopyranose
Synonyms:
3-Deoxy-1,2,4,6-tetra-O-acetyl-D-glucopyranose
CAS Number:
5040-09-5
Molecular Weight:
332.3
Molecular Formula:
C14H20O9
COA:
Inquire
MSDS:
Inquire
Structure:
Monosaccharides
Chemical Structure
CAS 5040-09-5 1,2,4,6-Tetra-O-acetyl-3-deoxy-D-glucopyranose

Related Monosaccharides Products


Reference Reading


1.Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.
Beesley VL1, Wockner LF2, O'Rourke P2, Janda M3, Goldstein D4,5, Gooden H6, Merrett ND7,8, O'Connell DL9, Rowlands IJ10, Wyld DK11,12, Neale RE2. Support Care Cancer. 2016 Apr 16. [Epub ahead of print]
PURPOSE: This study aims to determine if the supportive care needs of people with pancreatic cancer change over time and identify the factors associated with current and future unmet needs.
2.Prevalence of self-injury performed by adolescents aged 16-19 years.
Pawłowska B1, Potembska E2, Zygo M3, Olajossy M1, Dziurzyńska E4. Psychiatr Pol. 2016;50(1):29-42. doi: 10.12740/PP/36501.
OBJECTIVES: The aim of the study was to assess the prevalence of self-injury among adolescents aged 16-19 years and to indicate demographic variable, selected environmental variables and risky behaviours coexisting with performing self-injuries by the respondents.
3.Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
Hershman DL1,2,3, Kushi LH4, Hillyer GC5,6, Coromilas E7, Buono D6, Lamerato L8, Bovbjerg DH9,10, Mandelblatt JS11, Tsai WY12, Zhong X6, Jacobson JS5,6, Wright JD5,13, Neugut AI7,5,6. Breast Cancer Res Treat. 2016 Apr 16. [Epub ahead of print]
Non-adherence to adjuvant endocrine therapy (ET) for breast cancer (BC) is common. Our goal was to determine the associations between psychosocial factors and ET non-persistence. We recruited women with BC receiving care in an integrated healthcare system between 2006 and 2010. Using a subset of patients treated with ET, we investigated factors related to ET non-persistence (discontinuation) based on pharmacy records (≥90 days gap). Serial interviews were conducted at baseline and every 6 months. The Functional Assessment of Cancer Therapy (FACT), Medical Outcomes Survey, Treatment Satisfaction Questionnaire (TSQM), Impact of Events Scale (IES), Interpersonal Processes of Care measure, and Decision-making beliefs and concerns were measured. Multivariate models assessed factors associated with non-persistence. Of the 523 women in our final cohort who initiated ET and had a subsequent evaluation, 94 (18 %) were non-persistent over a 2-year follow-up.
4.Metastasis to the lymph nodes along the proper hepatic artery from adenocarcinoma of the stomach.
Kumagai K1, Hiki N2, Nunobe S1, Irino T1, Ida S1, Ohashi M1, Yamaguchi T1, Sano T1. Langenbecks Arch Surg. 2016 Apr 16. [Epub ahead of print]
PURPOSE: The study sought the significance of resecting lymph nodes along the proper hepatic artery (station 12a) in gastric cancer surgery and the possibility of predicting station 12a involvement from clinicopathological factors or metastatic status in other regional lymph nodes of the stomach.